Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
7Customers
1Debt Items
13Related Chains
Source-Backed Evidence Depth
AccuStem Sciences, Inc. (ACUT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
2Distinct source URLs
4High confidence
0.713Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
AccuStem Sciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
EMERITUSDX
EMERITUSDX
90%
The next milestone, transferring MSC from the laboratory in which it was originally developed to a commercial laboratory, EmeritusDx, located in Lake Forest, CA.
TIZIANA
TIZIANA
90%
We utilize approximately 75 square feet of office space in London from Tiziana for which we reimburse Tiziana at cost through a shared services agreement.
Reciprocal relationship from TLSA graph: Reciprocal relationship from ACUT graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from ACUT graph: Reciprocal relationship from TLSA g…
AccuStem Sciences, Inc. Customers
Ticker
Name
Confidence
Evidence
TIZIANA
TIZIANA
80%
The Company has also been formed due to an acquisition of a subsidiary company from Tiziana.
AMBRY-COLOR-HEALTH-FOUNDATION-MEDICINE-GUARDANT-
AMBRY-COLOR-HEALTH-FOUNDATION-MEDICINE-GUARDANT-
62%
obtaining established cohorts of patients and running prospective clinical trials that may demonstrate a broader utility for StemPrintER. Our commercialization plan for StemPrintER testing, beyond th…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
h and development expenses 119,525 28,346 91,179 322 % General and administrative expenses 366,358 412,062 (45,704 ) (11 %) Loss from operations 485,883 440,408 45,475 10 % Loss, before income tax (4…
NOVITAS-SOLUTIONS-INC
NOVITAS-SOLUTIONS-INC
62%
obtaining established cohorts of patients and running prospective clinical trials that may demonstrate a broader utility for StemPrintER. Our commercialization plan for StemPrintER testing, beyond th…
Reciprocal relationship from NVTS graph: Reciprocal relationship from ACUT graph: obtaining established cohorts of patients and running prospective clinical trials that may demonstrate a broader util…
PLANWISE-GROUP-LIMITED
PLANWISE-GROUP-LIMITED
62%
egulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. Our product candidates and the activities associated…
STEMPRINTER-SCIENCES-LIMITED
STEMPRINTER-SCIENCES-LIMITED
62%
ied body before it will renew the relevant certificate(s). All manufacturers placing in vitro diagnostic medical devices into the market in the EU must comply with the EU medical device vigilance sys…
AccuStem Sciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ACUT-DEBT-7491
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2025-12-31.
AccuStem Sciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for AccuStem Sciences, Inc..
AccuStem Sciences, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for AccuStem Sciences, Inc..
AccuStem Sciences, Inc. Extended Supply Chain Network
